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A BS T R AC T
BACKGROUND

Epidemiologic and preclinical data suggest that higher intake and serum levels of
vitamin D and higher intake of calcium reduce the risk of colorectal neoplasia. To
further study the chemopreventive potential of these nutrients, we conducted a
randomized, double-blind, placebo-controlled trial of supplementation with vitamin D, calcium, or both for the prevention of colorectal adenomas.

The authors’ affiliations are listed in the
Appendix. Address reprint requests to Dr.
Baron at the University of North Carolina
at Chapel Hill, CB #7555, 4160-A Bioinformatics Bldg., 130 Mason Farm Rd., Chapel
Hill NC 27599-7555, or at jabaron@med
.unc.edu.

METHODS

N Engl J Med 2015;373:1519-30.
DOI: 10.1056/NEJMoa1500409

We recruited patients with recently diagnosed adenomas and no known colorectal
polyps remaining after complete colonoscopy. We randomly assigned 2259 participants to receive daily vitamin D3 (1000 IU), calcium as carbonate (1200 mg), both,
or neither in a partial 2×2 factorial design. Women could elect to receive calcium
plus random assignment to vitamin D or placebo. Follow-up colonoscopy was
anticipated to be performed 3 or 5 years after the baseline examinations, according to the endoscopist’s recommendation. The primary end point was adenomas
diagnosed in the interval from randomization through the anticipated surveillance
colonoscopy.

Copyright © 2015 Massachusetts Medical Society.

RESULTS

Participants who were randomly assigned to receive vitamin D had a mean net
increase in serum 25-hydroxyvitamin D levels of 7.83 ng per milliliter, relative to
participants given placebo. Overall, 43% of participants had one or more adenomas diagnosed during follow-up. The adjusted risk ratios for recurrent adenomas
were 0.99 (95% confidence interval [CI], 0.89 to 1.09) with vitamin D versus no
vitamin D, 0.95 (95% CI, 0.85 to 1.06) with calcium versus no calcium, and 0.93
(95% CI, 0.80 to 1.08) with both agents versus neither agent. The findings for
advanced adenomas were similar. There were few serious adverse events.
CONCLUSIONS

Daily supplementation with vitamin D3 (1000 IU), calcium (1200 mg), or both after
removal of colorectal adenomas did not significantly reduce the risk of recurrent
colorectal adenomas over a period of 3 to 5 years. (Funded by the National Cancer
Institute; ClinicalTrials.gov number, NCT00153816.)
n engl j med 373;16
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itamin D, an essential nutrient
that is important for bone mineralization
and calcium homeostasis,1 also has effects
beyond bone and calcium. Many studies have
shown it to be antineoplastic, particularly in the
colorectum. In in vitro studies, vitamin D and its
analogues have been shown to inhibit proliferation, induce differentiation, inhibit angiogenesis,
and promote apoptosis in epithelial tissues.2,3
High vitamin D intake inhibits experimental
carcinogenesis,2,3 even in animals that are vitamin D–replete.4 Observational studies of vitamin D
intake5-7 and serum levels of 25-hydroxyvitamin
D8-10 have shown inverse associations between
these measures and the risk of colorectal cancer
or adenoma.8-10 Trials of vitamin D supplementation have not shown a decrease in the incidence
of colorectal cancer in association with supplementation,11-14 but these studies were limited by small
numbers of events,11-13 low vitamin D doses,14 and
relatively short follow-up periods for invasive
cancer end points.11-14
High calcium intake is also associated with
lower risks of colorectal neoplasia. Increases in
dietary calcium have been shown to inhibit largebowel carcinogenesis in animal models,15 and
epidemiologic studies have shown lower risks of
colorectal cancer and adenomas in association
with higher calcium intake.16 Trials of calcium
supplementation for adenoma prevention have
shown reduced risks.17-19 Moreover, calcium and
vitamin D may have synergistic chemopreventive
effects against colorectal neoplasia.20,21
To further investigate the chemopreventive
potential of vitamin D and calcium, we conducted
a randomized trial of supplementation with calcium, vitamin D3, or both for the prevention of
new colorectal adenomas in persons with a recent history of adenomas. We hypothesized that
supplementation would reduce the risk of adenoma and that both agents together would reduce
the risk more than calcium alone. Our secondary
hypotheses addressed the relationship between
vitamin D supplementation and the risk of advanced adenoma, as well as the effects of vitamin D supplementation among persons with
baseline 25-hydroxyvitamin D levels in blood that
were below the study median, as compared
with the effects in persons with levels above the
median.
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Me thods
Participants

We conducted this randomized, multicenter,
double-blind, placebo-controlled trial at 11 academic medical centers and associated medical
practices in the United States. Enrollment of
patients took place from July 2004 through July
2008. Staff members at each center enrolled
patients 45 to 75 years of age who had at least
one colorectal adenoma removed within 120 days
before enrollment, had no remaining polyps after
a complete colonoscopy, and were anticipated to
undergo a 3-year or 5-year colonoscopic followup examination recommended by the treating
endoscopist. Eligible patients were in good general health and did not have familial colorectal
cancer syndromes or serious intestinal disease.
We did not include patients who had conditions
that indicated that the study agents would pose
a health risk (e.g., a history of kidney stones or
hyperparathyroidism) or who had conditions that
would indicate a need for either agent (e.g., osteoporosis). We also did not include patients who
had a serum calcium level that was outside the
normal range, a creatinine level that was more
than 20% above the upper limit of the normal
range, or a 25-hydroxyvitamin D level that was
lower than 12 ng per milliliter or higher than
90 ng per milliliter.
Study Design and Oversight

In a partial factorial design, we evaluated four
regimens, all of which involved two identical
tablets taken daily: 1000 IU of vitamin D3, 1200 mg
of calcium as carbonate, both agents, or placebo.
Women could elect to be randomly assigned to
receive either calcium or calcium plus vitamin D
(two-group randomization); all other patients
were randomly assigned to receive one of the
four regimens (full factorial randomization).
The doses of study agents were chosen to increase the total intake substantially, with a margin of safety below the highest mean daily intake
level believed unlikely to cause adverse effects in
most people at the time that the trial began
(2000 IU of vitamin D and 2.5 g of calcium).22 In
accordance with the protocol, study treatment
was to continue until the anticipated 3-year or
5-year colonoscopic examination.
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At enrollment, participants provided information regarding demographic data, medical history, medications, nutritional supplements, behavioral factors, and diet (using the Block Brief 2000
food frequency questionnaire [Nutritionquest]).
Enrollment was followed by a placebo run-in
period of 56 to 84 days to identify and exclude
participants who were considered unlikely to follow study procedures. Subsequent randomization by the coordinating center was performed
with the use of computer-generated random
numbers with permuted blocks and stratification
according to clinical center, sex, anticipated
colonoscopic examination at 3 years or 5 years,
and full factorial or two-group randomization.
All study staff were unaware of the treatment
assignments, with the exception of the data analyst and statistician, some of the programmers,
and pharmacy personnel.
Participants agreed to avoid taking study
agents outside the trial. However, because of increasing publicity regarding the possible benefits of these supplements (especially vitamin D),
daily personal use of up to 1000 IU of vitamin D,
400 mg of elemental calcium, or both were permitted, although discouraged, from April 2008
onward.
Participants were contacted by telephone
every 6 months and queried regarding adherence
to study agents, illnesses, medication and supplement use, dietary calcium intake (see the
Supplementary Appendix, available with the full
text of this article at NEJM.org), and colorectal
procedures. Records were collected that included
data on major medical events, colorectal surgical
procedures, and endoscopic examinations. Two
physicians who were unaware of the study group
assignments adjudicated the diagnosis of adverse
events. Bottles of study tablets were mailed to
participants every 4 months. Patients who wanted
to take a multivitamin were offered a special
preparation that did not include calcium and
vitamin D. The study intervention ended on
August 31, 2013; the treatment-phase follow-up
continued until November 30, 2013, to accommodate the final 5-year participants.
Blood levels of 25-hydroxyvitamin D, calcium,
and creatinine were measured at baseline and at
year 1, as well as at year 3 for participants with
5-year surveillance cycles. The level of 25-hydroxy

n engl j med 373;16

vitamin D was also measured shortly before the
end-of-treatment examination. The laboratory
methods are described in the Supplementary Appendix. Levels of 25-hydroxyvitamin D were
seasonally adjusted according to the month in
which the blood was drawn (see the Supplementary Appendix). The net change in 25-hydroxyvitamin D levels was defined as the posttreatment
level minus the pretreatment level in participants
who received vitamin D, minus that difference in
participants who were given no vitamin D.
The study end points included all adenomas
that were diagnosed in any colorectal endoscopic or surgical procedure at least 1 year after
randomization and up to 6 months after the
anticipated 3-year or 5-year colonoscopic examination. A single study pathologist who was unaware of the treatment assignments reviewed the
slides for all excised colorectal lesions. We distinguished between lesions that were proximal
to the splenic flexure and lesions that were more
distal. Advanced adenomas were defined as those
with cancer, high-grade dysplasia, more than
25% villous features, or an estimated diameter
of at least 1 cm. Study diagnoses were compared
with the diagnoses made by the pathologists at
the clinical centers. Discrepancies were resolved
by means of a detailed adjudication procedure
(see the Supplementary Appendix).
The study was conducted and reported in accordance with the study protocol, which is available at NEJM.org. The authors designed the study,
analyzed the data, wrote the manuscript, and
vouch for the completeness and accuracy of the
data and analysis. Pfizer Consumer Healthcare
provided the study agents. No institution or
company affected the analysis or the decision to
submit the manuscript for publication.
All participants provided written informed
consent; the research was approved by the institutional review board at each center. An independent data and safety monitoring committee
oversaw the study.
Statistical Analysis

In our primary analysis, we compared the risk of
one or more adenomas after randomization to
vitamin D versus no vitamin D, calcium versus
no calcium, and calcium plus vitamin D versus
calcium alone. Participants who did not undergo
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Relative Risk (95% CI)

Subgroup

m e dic i n e

Calcium
Relative Risk (95% CI)

P Value

0.99 (0.89–1.09)

Overall
Baseline serum 25-hydroxyvitamin D
≤23.16 ng/ml
>23.16 ng/ml
Baseline dietary calcium
≤597 mg/day
>597 mg/day
Sex
Male
Female
BMI
<25
25–29.9
≥30
Baseline supplement use
<400 IU/day vitamin D or mg/day calcium
≥400 IU/day vitamin D or mg/day calcium
Cigarette smoking
Never or former
Current
Alcohol use
0 drinks/day
0.1–1 drinks/day
>1 drink/day
Baseline NSAID or aspirin use
<4 days/wk
≥4 days/wk
Anticipated surveillance interval
3 yr
5 yr
0.0

of

0.95 (0.85–1.06)
0.26

0.20

1.05 (0.91–1.21)
0.94 (0.81–1.08)

1.01 (0.87–1.18)
0.88 (0.75–1.03)
0.28

0.55

0.91 (0.79–1.04)
1.02 (0.87–1.19)

0.90 (0.78–1.05)
0.97 (0.82–1.15)
0.87

0.46

0.99 (0.88–1.11)
0.98 (0.80–1.19)

0.93 (0.83–1.05)
1.03 (0.74–1.42)
0.39

0.02

0.88 (0.70–1.12)
1.02 (0.87–1.20)
1.03 (0.87–1.21)

0.75 (0.58–0.98)
0.93 (0.78–1.10)
1.08 (0.91–1.29)
0.29

0.93

0.94 (0.81–1.08)
1.04 (0.90–1.21)

0.95 (0.85–1.07)
0.87 (0.51–1.48)
0.64

0.34

0.98 (0.88–1.09)
0.99 (0.72–1.35)

0.93 (0.83–1.04)
1.28 (0.87–1.86)
0.54

0.24

0.85 (0.71–1.02)
1.10 (0.92–1.32)
0.98 (0.81–1.19)

0.87 (0.71–1.07)
1.12 (0.92–1.36)
0.83 (0.68–1.02)
0.52

0.69

1.02 (0.88–1.17)
0.95 (0.82–1.10)

0.96 (0.82–1.12)
0.92 (0.79–1.08)
0.28

0.47

1.04 (0.90–1.19)
0.93 (0.80–1.08)
1.0

P Value

0.98 (0.84–1.14)
0.90 (0.77–1.05)

1.5

0.0

1.0

1.5

Figure 1. Subgroup Analysis of the Effects of Supplementation with Calcium or Vitamin D on the Development of One or More Adenomas.
The body-mass index (BMI) is the weight in kilograms divided by the square of the height in meters. NSAID denotes nonsteroidal anti
inflammatory drug.

the anticipated colonoscopic examination at 3 years
or 5 years were included in the analysis if they
had had a colonoscopic examination performed
at least 1 year after randomization. The sample
size and statistical power considerations are
described in the Supplementary Appendix.
In the prespecified primary analysis, contingency tables and standard chi-square tests were
used for the comparison of adenoma occurrence
among randomized groups. The calcium analyses included only the participants who underwent full-factorial randomization. Subsequent
multivariable generalized linear models for binary data were used to estimate adjusted risk
ratios and confidence intervals. The covariates
were age, sex, clinical center, number of baseline
adenomas (one, two, or three or more), antici1522
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pated 3-year versus 5-year surveillance interval,
and two-group versus full-factorial randomization. Clinical centers were grouped geographically when necessary because of sparse data.
One subgroup analysis was prespecified: the effects of vitamin D in participants with baseline
25-hydroxyvitamin D levels below the overall
median level were compared with the effects in
those with levels above the median level. Eight
additional post hoc subgroup analyses were conducted, as described in Figure 1. Interactions
were assessed with the use of Wald tests. For
interactions with variables that had more than
two levels, we used a one-degree-of-freedom test
for trend over medians within strata. In all analyses of randomly assigned treatments, participants
were evaluated according to their assigned treat-
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ment group, regardless of their adherence to the
study treatment and procedures. Sensitivity analyses were conducted with imputation of missing
end points as either adenomas or no adenomas.
In a post hoc observational analysis, we similarly assessed associations between adenoma
risk and baseline serum 25-hydroxyvitamin D
levels among participants who were not randomly assigned to take vitamin D, as well as the
association between adenoma risk and baseline
calcium intake among participants who were not
randomly assigned to receive calcium. The analyses were adjusted for a number of covariates,
including (but not limited to) age, clinical center,
surveillance interval (3 or 5 years), and number of
baseline adenomas (one, two, or three or more).
Two-sided P values of less than 0.05 were
considered to indicate statistical significance.
Statistical analyses were conducted with the use
of SAS software, version 9.4 (SAS Institute), and
STATA software, version 12 (StataCorp).

R e sult s
Participants

During the period from July 2004 through July
2008, the study staff screened colonoscopy and
pathology reports and found 19,083 apparently
eligible patients (Fig. S1 in the Supplementary
Appendix). Ultimately, 2813 participants entered
the run-in period, and 2259 underwent randomization. The study population was middle-aged
or older; most patients were non-Hispanic men,
and more than 35% of the patients were obese
(Table 1). A total of 11% of the participants had
three or more adenomas at baseline, and 18%
had one or more advanced adenomas. There
were no material differences between treatment
groups with regard to personal characteristics
(Table 1). Fifteen patients who underwent randomization and were included in the analysis
were later found not to have met all eligibility
criteria (see the Supplementary Appendix).
Adherence to the Study Procedures

The reported adherence to colonoscopy was excellent. Only 67 participants (3.0%) did not have a
colonoscopic examination with associated histologic data at least 1 year after randomization,
and 104 participants (4.6%) dropped out of the
study, were lost to follow-up, or died; this left
2088 participants (92.4%) in the analysis (Fig. S1
n engl j med 373;16

in the Supplementary Appendix). Only approximately 1% of the colonoscopic examinations
failed to reach the cecum; in 2.0% of procedures, the preparation of the colon was deemed
“poor,” and in 6.8% it was deemed “fair.” The
times to final colonoscopic examination are
summarized in Table S2 in the Supplementary
Appendix. A total of 1598 participants (77%) had
a surveillance colonoscopic examination within
6 months before or after the anticipated 3-year
or 5-year follow-up examination. A total of 60
participants (2.9%) had more than one colonoscopic examination during follow-up.
During the first year after randomization,
1974 of the 2259 participants who underwent
randomization (87.4%) reported taking 80% or
more of the study tablets; in the final year of
treatment, 1663 participants (73.6%) reported
this level of adherence. During the treatment
period, 1719 participants (76.1%) reported taking at least 80% of the study tablets, and 1949
(86.3%) reported taking at least 50%. Only 98 of
2251 participants for whom data on personal
vitamin supplementation were available (4.4%)
reported on two or more semiannual interviews
that they took personal vitamin D supplements
of 1000 IU or more daily, 74 (3.3%) reported that
they took 400 mg or more of calcium daily, and
78 (3.5%) reported that they took 500 to less
than 1000 IU of vitamin D. The mean (±SD) net
increase in serum 25-hydroxyvitamin D among
participants randomly assigned to vitamin D was
7.83±13.4 ng per milliliter in a blood sample
drawn shortly before the end of treatment.
Occurrence of Adenomas

In follow-up examinations, 3131 lesions that were
potentially neoplastic were seen in 1301 participants. Pathological evaluations were available for
3012 lesions in 1280 participants. For 119 lesions, the tissue was lost, fulgurated without
biopsy, or unsuitable for diagnosis; this left 2059
(99%) of the examined participants for whom
we could determine adenoma status. Adenomas
were diagnosed in 880 participants (43%).
Effects of Supplementation

The study interventions, alone or in combination, did not have a significant effect on the risk
of adenoma (Table 2). The adjusted risk ratio for
any adenoma among patients taking vitamin D
as compared with patients who did not take vita-
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7/404 (1.7)

8/402 (2.0)

35 (8.4)

Current smoker

0.89±1.08
672±313

Alcohol intake — drinks/day

Dietary calcium intake — mg/day

69/399 (17.3)

193 (46.5)

Former smoker

At least one advanced adenoma at baseline — no./total
no. (%)

187 (45.1)

147/414 (35.5)

Never smoked

Smoking status — no. (%)

BMI ≥30 — no./total no. (%)‡

718±326

0.82±1.01

79/399 (19.8)

33 (7.9)

174 (41.5)

212 (50.6)

165/419 (39.4)

29.5±5.1

77/395 (19.5)

3/404 (0.7)

643±286

0.91±1.11

80/398 (20.1)

39 (9.3)

164 (39.0)

217 (51.7)

163/420 (38.8)

29.1±4.6

66/391 (16.9)

396/420 (94.3)

652±303

0.89±1.08

76/404 (18.8)

48 (11.4)

169 (40.1)

204 (48.5)

144/421 (34.2)

29.0±5.1

75/393 (19.1)

394/420 (93.8)

2/404 (0.5)

6/404 (1.5)

46/404 (11.4)

350/404 (86.6)

58.7±6.9

354 (84.1)

67 (15.9)

Vitamin D plus
Calcium
(N = 421)

604±295

0.40±0.72

56/289 (19.4)

28 (9.5)

62 (21.0)

205 (69.5)

112/294 (38.1)

28.8±6.0

52/279 (18.6)

267/295 (90.5)

1/275 (0.4)

8/275 (2.9)

28/275 (10.2)

238/275 (86.5)

56.7±6.0

0

295 (100)

Calcium plus
Placebo
(N = 295)

656±313

0.48±0.69

47/281 (16.7)

32 (11.1)

88 (30.4)

169 (58.5)

92/288 (31.9)

28.3±5.4

43/270 (15.9)

263/289 (91.0)

2/271 (0.7)

7/271 (2.6)

25/271 (9.2)

237/271 (87.5)

57.0±6.6

0

289 (100)

Calcium plus
Vitamin D
(N = 289)

of

29.0±4.9

59/378 (15.6)

Family history of colorectal cancer — no./total no. (%)

395/418 (94.5)

12/404 (3.0)

25/404 (6.2)

364/404 (90.1)

58.3±7.0

358 (85.2)

62 (14.8)

Vitamin D
(N = 420)

Two-Group Randomization

n e w e ng l a n d j o u r na l

BMI‡

395/414 (95.4)

Non-Hispanic ethnic background — no./total no. (%)†

Other

10/404 (2.5)

10/402 (2.5)

Asian or Pacific Islander

33/404 (8.2)

27/402 (6.7)

Black

354/404 (87.6)

357/402 (88.8)

White

Race — no./total no. (%)†

58.2±7.0

58.7±7.0

356 (85.0)

355 (85.5)

Male

Age — yr

Calcium
(N = 419)

63 (15.0)

Placebo
(N = 415)

Full Factorial Randomization

60 (14.5)

Female

Sex — no. (%)

Characteristic

Table 1. Selected Baseline Characteristics According to Treatment Assignment.*

The

m e dic i n e

October 15, 2015

The New England Journal of Medicine
Downloaded from nejm.org at DARTMOUTH HITCHCOCK MED CTR on October 15, 2015. For personal use only. No other uses without permission.
Copyright © 2015 Massachusetts Medical Society. All rights reserved.

n engl j med 373;16

12/391 (3.1)

≥500 IU/day

nejm.org

160 (38.6)

≥4 days/wk

October 15, 2015

43 (10.4)

≥4 days/wk

52 (12.4)

367 (87.6)

170 (40.6)

249 (59.4)

24.58±8.42

16/389 (4.1)

170/389 (43.7)

203/389 (52.2)

41 (9.8)

379 (90.2)

165 (39.3)

255 (60.7)

24.88±8.09

26/397 (6.5)

162/397 (40.8)

209/397 (52.6)

131±102

17/396 (4.3)

172/396 (43.4)

207/396 (52.3)

Vitamin D
(N = 420)

33 (7.8)

388 (92.2)

151 (35.9)

270 (64.1)

24.45±8.06

12/397 (3.0)

175/397 (44.1)

210/397 (52.9)

130±92

19/400 (4.8)

169/400 (42.2)

212/400 (53.0)

Vitamin D plus
Calcium
(N = 421)

34 (11.5)

261 (88.5)

68 (23.1)

227 (76.9)

25.03±8.90

42/246 (17.1)

120/246 (48.8)

84/246 (34.1)

124±96

99/257 (38.5)

94/257 (36.6)

64/257 (24.9)

Calcium plus
Placebo
(N = 295)

36 (12.5)

253 (87.5)

83 (28.7)

206 (71.3)

24.29±7.71

52/233 (22.3)

110/233 (47.2)

71/233 (30.5)

134±98

113/255 (44.3)

86/255 (33.7)

56/255 (22.0)

Calcium plus
Vitamin D
(N = 289)

Two-Group Randomization

*	Plus–minus values are means ±SD. The table includes all participants who underwent randomization. Women could elect to be randomly assigned to receive either calcium plus placebo or calcium plus vitamin D (two-group randomization); all other patients were randomly assigned to receive one of four regimens: vitamin D, calcium, both agents, or placebo (full
factorial randomization). NSAID denotes nonsteroidal antiinflammatory drug.
†	Race and ethnic background were self-reported.
‡	The body-mass index (BMI) is the weight in kilograms divided by the square of the height in meters. A BMI of 30 or higher indicates obesity.
§	Supplemental values include those from separate supplements and multivitamins. Participants were asked to stop taking these personal supplements at enrollment as a condition of
study entry. However, from April 2008 onward, daily personal use of up to 1000 IU of vitamin D, 400 mg of elemental calcium, or both were permitted, although discouraged. Patients
who wanted to take a multivitamin were offered a special preparation that did not include calcium and vitamin D.

372 (89.6)

<4 days/wk

Baseline non-aspirin NSAID use — no. (%)

255 (61.4)

<4 days/wk

Baseline aspirin use — no. (%)

24.24±7.84

175/391 (44.8)

1–499 IU/day

Baseline serum 25-hydroxyvitamin D level — ng/ml

204/391 (52.2)

None

Baseline supplemental vitamin D intake — no./total no.
(%)§

146±96

22/393 (5.6)

138±97

13/387 (3.4)

Baseline dietary vitamin D intake — IU/day

≥500 elemental mg/day

172/393 (43.8)

201/387 (51.9)
173/387 (44.7)

199/393 (50.6)

Calcium
(N = 419)

None

Placebo
(N = 415)

Full Factorial Randomization

1–499 elemental mg/day

Baseline supplemental calcium intake — no./total no. (%)§

Characteristic
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Table 2. Risk Ratios for Colorectal Adenoma Outcomes According to Treatment Assignment.*
Treatment Assignment

One or More Adenomas†

One or More Advanced Adenomas‡

No. of Patients/
Total No. (%)

Risk Ratio
(95% CI)§

No. of Patients/
Total No. (%)

Risk Ratio
(95% CI)§

No vitamin D

442/1035 (42.7)

Reference

98/1042 (9.4)

Reference

Vitamin D

438/1024 (42.8)

0.99 (0.89–1.09)

98/1032 (9.5)

0.99 (0.75–1.29)

Vitamin D vs. no vitamin D

Calcium vs. no calcium
No calcium

362/761 (47.6)

Reference

77/764 (10.1)

Reference

Calcium

345/762 (45.3)

0.95 (0.85–1.06)

81/773 (10.5)

1.02 (0.76–1.38)

Calcium

259/655 (39.5)

Reference

63/662 (9.5)

Reference

Calcium plus vitamin D

259/643 (40.3)

1.01 (0.88–1.15)

56/648 (8.6)

0.89 (0.63–1.26)

Neither calcium nor vitamin D

183/380 (48.2)

Reference

35/380 (9.2)

Reference

Calcium plus vitamin D

174/381 (45.7)

0.93 (0.80–1.08)

37/387 (9.6)

0.99 (0.63–1.56)

Calcium plus vitamin D vs. calcium
alone

Calcium plus vitamin D vs. neither
agent

*	The analyses of vitamin D versus no vitamin D included all participants who underwent randomization. The analyses
of calcium versus no calcium and of vitamin D plus calcium versus neither agent were restricted to participants who
underwent full factorial randomization. The analyses of vitamin D plus calcium versus calcium did not include participants who underwent full factorial randomization and were assigned to receive placebo or vitamin D alone.
†	P values, calculated with the use of a chi-square contingency-table test, are as follows: vitamin D versus no vitamin D,
P = 0.98; calcium versus no calcium, P = 0.37; vitamin D plus calcium versus calcium, P = 0.79; and vitamin D plus calcium
versus neither agent, P = 0.49.
‡	Denominators differ between adenomas and advanced adenomas because of missing data for lesion size and an assumption that small lesions (<6 mm) with missing pathological data are not advanced adenomas (see the Supplementary
Appendix).
§	Risk ratios were adjusted for age, clinical center, anticipated surveillance interval (3 or 5 years), a three-level variable for
sex and type of randomization (male, female and two-group randomization, female and full factorial randomization),
and number of baseline adenomas (1, 2, or ≥3).

min D was 0.99 (95% confidence interval [CI],
0.89 to 1.09), and the adjusted risk ratio among
patients taking calcium as compared with those
who did not take calcium was 0.95 (95% CI, 0.85
to 1.06). Among patients taking vitamin D plus
calcium versus those taking calcium alone, the
adjusted risk ratio was 1.01 (95% CI, 0.88 to
1.15). The adjusted risk ratio among patients
taking vitamin D plus calcium versus those taking neither agent was 0.93 (95% CI, 0.80 to
1.08). The findings for advanced adenomas also
did not suggest meaningful effects. The results
for proximal adenomas were similar to those for
distal adenomas (Table S3 in the Supplementary
Appendix).
In the subgroup analyses, we found almost
no significant effects of supplementation (Fig. 1,
and Fig. S2 in the Supplementary Appendix). The
findings were similar among participants with
1526
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baseline 25-hydroxyvitamin D levels below the
study median of 23.2 ng per milliliter and those
with levels above the study median. However,
body-mass index (BMI) appeared to modify the
effects of calcium on adenoma risk (P = 0.02): the
lower the BMI, the greater the response to calcium supplementation. Findings with respect to
advanced adenomas were broadly similar to
those for all adenomas (Fig. 1, and Fig. S2 in the
Supplementary Appendix). The findings did not
differ significantly between participants who
were using vitamin D or calcium supplements at
baseline and those who were not or between
those who had advanced adenomas at baseline
and those who did not (Tables S4, S5, and S6 in
the Supplementary Appendix). There were no
indications of effects in a per-protocol analysis,
nor was there an association between adenoma
risk and changes in 25-hydroxyvitamin D levels
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Table 3. Adverse Events.*
Adverse Event

Vitamin D versus No Vitamin D
No Vitamin D
(N = 1129)

Vitamin D
(N = 1130)

P Value

Calcium versus No Calcium
No Calcium
(N = 835)

number (percent)
Death

Calcium
(N = 840)

P Value

number (percent)

12 (1.1)

15 (1.3)

0.56

12 (1.4)

13 (1.5)

0.85

Myocardial infarction with or without revascularization

7 (0.6)

8 (0.7)

0.80

9 (1.1)

2 (0.2)

0.03

Revascularization without myocardial infarction

11 (1.0)

12 (1.1)

0.84

8 (1.0)

12 (1.4)

0.38

Stroke

5 (0.4)

9 (0.8)

0.28

5 (0.6)

3 (0.4)

0.51

Transient ischemic attack

1 (0.1)

3 (0.3)

0.62

3 (0.4)

0

0.12

61 (5.4)

47 (4.2)

0.17

46 (5.5)

46 (5.5)

0.98

2 (0.2)

3 (0.3)

1.00

0

2 (0.2)

0.50

Cancer
Any
Colorectal
Urolithiasis

28 (2.5)

19 (1.7)

0.18

15 (1.8)

20 (2.4)

0.40

Hypercreatininemia†

67 (6.0)

57 (5.1)

0.35

40 (4.9)

58 (7.0)

0.06

Hypercalcemia‡

28 (2.5)

25 (2.2)

0.67

5 (0.6)

17 (2.0)

0.01

4 (0.4)

3 (0.3)

1.00

0

2 (0.2)

0.50

64 (5.7)

55 (4.9)

0.39

43 (5.1)

37 (4.4)

0.47

Hypercalcemia after albumin
correction§
Fracture

*	The table includes all confirmed events up to 30 days after the cessation of study treatment in all participants who underwent randomization. Data are the numbers of participants who had one or more occurrences of an adverse event and
their percentage among all participants who were randomly assigned to the given group.
†	Hypercreatininemia was defined as a creatinine level in the blood sample drawn at year 1 (all participants) or year 3
(participants with a 5-year follow-up) that was above the normal range among participants who had creatinine levels
in the normal range at baseline; 31 participants had baseline creatinine levels that were above the normal range. Data
were available for 1113 participants in the group that received no vitamin D, 1115 participants in the group that received
vitamin D, 822 participants in the group that received no calcium, and 825 participants in the group that received calcium.
‡	Hypercalcemia was defined as a calcium level in the blood sample drawn at year 1 or year 3 that was above the normal
range, before albumin correction.
§	Albumin correction was not available for 12 participants.

or total calcium intake from baseline to shortly
before the end of treatment (Tables S7 and S8 in
the Supplementary Appendix). However, there
was a suggestion that supplementation with vitamin D or calcium conferred lower risks among
participants with longer surveillance (and treatment) intervals, although the differences were
not significant (Fig. 1, and Table S9 in the Supplementary Appendix). The sensitivity analysis
did not suggest that missing data distorted the
primary analyses (Table S10 in the Supplementary Appendix).
Adverse events are shown in Table 3. Calcium
supplementation was associated with a small,
nonsignificantly greater risk of urolithiasis than
no calcium supplementation, and vitamin D supplementation was associated with a nonsignificantly lower risk of urolithiasis than no vitan engl j med 373;16

min D supplementation. Participants who were
randomly assigned to take calcium had slightly
higher serum creatinine levels than did participants who were not assigned to take calcium;
the difference was of borderline significance. In
addition, participants assigned to take calcium
had significantly fewer myocardial infarctions
than participants who were assigned to no calcium supplementation.
The observational associations between adenoma occurrence and baseline serum 25-hydroxyvitamin D level or baseline calcium intake roughly
paralleled the findings for supplementation with
vitamin D or calcium (Table 4). Among participants who were not given vitamin D, baseline
25-hydroxyvitamin D levels were not significantly
associated with adenoma risk (risk ratio, quartile 4 vs. quartile 1, 0.98; 95% CI, 0.79 to 1.21).
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Table 4. Observational Association of Baseline Serum 25-Hydroxyvitamin D Level and Dietary Calcium Intake with Risk of Colorectal
Adenoma.
Quartile of Level or Intake*

Baseline Serum 25-Hydroxyvitamin D Level†
No. of Patients/
Total No. (%)

Adjusted Risk
Ratio
(95% CI)§

Baseline Dietary Calcium Intake‡

Adjusted Risk Ratio
Adjusted Risk
Adjusted Risk
per 10 ng/ml
No. of Patients/
Ratio
Ratio per 200 mg
(95% CI)
Total No. (%)
(95% CI)¶
(95% CI)
0.98
(0.90–1.07)

Participants with one or more
adenomas

0.99
(0.93–1.04)

Quartile 1

108/256 (42.2)

Reference

89/179 (49.7)

Reference

Quartile 2

115/271 (42.4)

1.02
(0.83–1.25)

94/170 (55.3)

1.17
(0.95–1.46)

Quartile 3

117/257 (45.5)

1.06
(0.86–1.30)

69/170 (40.6)

0.85
(0.65–1.08)

Quartile 4

102/251 (40.6)

0.98
(0.79–1.21)

84/184 (45.7)

0.95
(0.75–1.19)

0.91
(0.71–1.16)

Participants with one or more
advanced adenomas‖

0.94
(0.80–1.10)

Quartile 1

25/257 (9.7)

Reference

21/176 (11.9)

Reference

Quartile 2

28/270 (10.4)

1.11
(0.66–1.88)

15/176 (8.5)

0.72
(0.38–1.36)

Quartile 3

21/263 (8.0)

0.83
(0.47–1.46)

19/170 (11.2)

0.96
(0.52–1.75)

Quartile 4

24/252 (9.5)

1.06
(0.61–1.83)

18/185 (9.7)

0.82
(0.44–1.53)

*	For 25-hydroxyvitamin D, quartiles of seasonally adjusted values were as follows: quartile 1, ≤18.411 IU; quartile 2, 18.412 to 23.178 IU;
quartile 3, 23.179 to 29.326 IU; and quartile 4, ≥29.327 IU. For calcium intake, the quartiles were as follows: quartile 1, up to 435.7 mg;
quartile 2, 437.8 to 596.7 mg; quartile 3, 596.8 to 831.2 mg; and quartile 4, ≥831.3 mg.
†	The analysis was restricted to participants who did not receive study vitamin D supplementation; risk ratios were adjusted for age, clinical
center, anticipated surveillance interval (3 or 5 years), a three-level variable for sex and type of randomization (male, female and two-group
randomization, female and full factorial randomization), number of baseline adenomas (one, two, or three or more), and calcium treatment
assignment (participants who underwent two-group randomization are grouped with participants who underwent full factorial randomization and received calcium).
‡	The analysis was restricted to participants who underwent full factorial randomization and did not receive study calcium supplementation;
risk ratios were adjusted for age, clinical center, anticipated surveillance interval (3 or 5 years), sex, number of baseline adenomas (one, two, or
three or more), and vitamin D treatment assignment; because of sparse data for advanced adenomas, clinical centers are grouped geographically into southeast (Georgia, North Carolina, South Carolina, and Puerto Rico), north (Ohio, New Hampshire, Iowa, and Minnesota), and
west (Colorado, Texas, and California).
§	The P value for trend for adenomas was 0.86, and the P value for trend for advanced adenomas was 0.95.
¶	The P value for trend for adenomas was 0.33, and the P value for trend for advanced adenomas was 0.99.
‖	Denominators differ between adenomas and advanced adenomas because of missing data on lesion size and an assumption that small lesions
(<6 mm) with missing pathological data are not advanced adenomas (see the Supplementary Appendix).

The results for baseline calcium intake among
participants who were not given calcium were
similar (risk ratio, quartile 4 vs. quartile 1, 0.95;
95% CI, 0.75 to 1.19). We also found no observational associations between the risk of advanced adenomas and baseline serum 25-hydrox
yvitamin D level or baseline calcium intake.

colorectal adenomas. The findings were similar
with regard to the risk of advanced adenomas,
and vitamin D supplementation was ineffective
even among participants who had lower baseline
serum 25-hydroxyvitamin D levels. Unplanned
subgroup analyses based on participant characteristics at baseline yielded similar results, with
the exception of a lower risk of adenomas in association with calcium supplementation among
Discussion
participants with lower BMIs. Because of the
Contrary to our hypotheses, neither 1000 IU of number of subgroups examined, this finding may
vitamin D3 nor 1200 mg of calcium, taken daily be due to chance. In observational analyses, we
alone or in combination, reduced the risk of also found no association between either baseline
1528
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25-hydroxyvitamin D levels or dietary calcium
intake and the risk of adenomas or advanced
adenomas.
Our study dose of vitamin D (1000 IU per day)
exceeded the currently recommended intake for
adults up to 70 years of age (600 IU per day).
However, a higher dose would have raised 25-hydroxyvitamin D levels in serum more markedly
and provided a more sensitive test of vitamin D
chemoprevention. Meta-analyses have summarized the observational association between serum 25-hydroxyvitamin D level and colorectal
cancer as relative risks of 0.74 per 10 ng per
milliliter,6 0.85 per 10 ng per milliliter,23 and
0.96 per 100 IU per liter5 (0.85 per 10 ng per
milliliter). These associations suggest that the net
mean increase of 7.83 ng per milliliter in serum
25-hydroxyvitamin D levels in our study might
yield a relative risk between 0.80 and 0.88,
which is outside our confidence limits for all
adenomas. In this sense, our findings provide
evidence against the strong observational association reported in these meta-analyses.
A report of increasing colorectal cancer risk
with increasing 25-hydroxyvitamin D levels24 was
included in one meta-analysis9 that yielded a
summary relative risk of 0.94 per 10 nmol per
liter (0.90 per 10 ng per milliliter). This suggests
that the increase of 7.83 ng per milliliter in
25-hydroxyvitamin D levels in our study might
yield a relative risk of 0.92, which is within our
confidence intervals and so statistically consistent with our data. Meta-analyses of the relationship between adenoma risk and serum 25-hydrox
yvitamin D levels8,10 have shown summary
relative risks between 0.82 and 0.93 per 20 ng per
milliliter (0.93 to 0.97 per 7.75 ng per milliliter).
Again, our data are consistent with this weaker
association.8,10 A larger sample size, higher vitamin D dose, or perhaps a longer intervention
might have been required to detect these associations. Also, the fact that vitamin D may have
a weaker relationship with adenomas than with
colorectal cancer might imply that vitamin D acts
at a later stage of carcinogenesis than that at
which adenomas develop.
In view of the strong data supporting a chemopreventive effect of calcium supplementation on
colorectal carcinogenesis15,16,18,19 (including findings in our own previous trial),17 it is surprising
that we found no effect of calcium. However, the
lack of association between baseline dietary caln engl j med 373;16

cium intake and adenoma risk observed in our
study population supports the negative findings
for calcium in our trial. Whether the high prevalence of obesity in our study population explains
the lack of a calcium effect requires further investigation.
Important adverse events in the trial were
generally uncommon. However, calcium supplementation resulted in an unexpected, small increase in serum creatinine level,25 which was of
uncertain clinical significance. There was a significantly lower risk of myocardial infarction
among participants randomly assigned to receive
calcium, a finding that contrasts with recent
evidence.26 The lower cancer risk associated with
vitamin D supplementation and the smaller number of participants receiving vitamin D or calcium
in whom fractures occurred were all compatible
with chance.
Our trial had several strengths. It was large
enough to detect modest chemopreventive effects,
adherence to study treatment was high, and participants largely avoided taking vitamin D and
calcium in substantial amounts outside the
study. We obtained findings from a follow-up
colonoscopic examination in a high proportion
of participants, and virtually all lesions underwent central pathological review. However, the
vitamin D dose was lower than the dose many
experts now recommend, and it was used for a
limited time. The trial was conducted among
patients with a recent history of colorectal adenomas, and the results might not apply to persons
without such a history.
In summary, contrary to our expectation,
supplementation with 1000 IU of vitamin D3,
1200 mg of calcium, or both did not significantly affect the risk of colorectal adenomas over
a period of 3 to 5 years. We have no ready explanation for the finding with regard to calcium
supplementation, but the lack of an observational association between the risk of adenomas
and baseline dietary calcium intake in our population supports it. Our findings with regard to
vitamin D are not inconsistent with a modest
chemopreventive potential, but they do not support the more marked chemopreventive effect
that has sometimes been posited.
Supported by a grant from the National Institutes of Health,
National Cancer Institute (CA098286, to Dr. Baron).
Disclosure forms provided by the authors are available with
the full text of this article at NEJM.org.

nejm.org

October 15, 2015

1529

The New England Journal of Medicine
Downloaded from nejm.org at DARTMOUTH HITCHCOCK MED CTR on October 15, 2015. For personal use only. No other uses without permission.
Copyright © 2015 Massachusetts Medical Society. All rights reserved.

Calcium and Vitamin D for the Prevention of Adenomas

Appendix
The authors’ affiliations are as follows: the Departments of Medicine (J.A.B., D.J.R., R.R.) and Epidemiology (J.A.B., E.L.B., L.A.M.,
J.R.R.), Geisel School of Medicine at Dartmouth, Hanover, and Department of Medicine, Dartmouth–Hitchcock Medical Center, Lebanon (D.J.R., R.R.) — both in New Hampshire; the Departments of Medicine (J.A.B., R.S.S.) and Biostatistics (A.I.), University of North
Carolina at Chapel Hill, Chapel Hill; the Department of Pathology, Fairview Southdale Hospital, Edina (D.C.S.), and the Division of
Environmental Health Sciences, University of Minnesota School of Public Health (T.R.C.), Minnesota Gastroenterology (A.S.K.), Department of Medicine, University of Minnesota (A.S.), and Minneapolis Veterans Affairs (VA) Medical Center (A.S.), Minneapolis — all in
Minnesota; the Department of Epidemiology, Rollins School of Public Health, Emory University and Winship Cancer Institute, Emory
University, Atlanta (R.M.B., M.G.); the Department of Mathematics and Statistics, University of Vermont, Burlington (B.F.C.), and VA
Outcomes Group, White River Junction (D.J.R.) — both in Vermont; the Department of Medicine, University of Colorado School of
Medicine, Denver (D.J.A.); the Departments of Quantitative Health Sciences (G.J.B.) and Gastroenterology and Hepatology (C.A.B.),
Cleveland Clinic, Cleveland; the Department of Gastroenterology, Hepatology, and Nutrition, University of Texas M.D. Anderson Cancer
Center, Houston (R.S.B.); Puerto Rico Cancer Center, Medical Sciences Campus, University of Puerto Rico, San Juan (M.C.-C.); the
Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles (J.C.F.); Consultants in
Gastroenterology, West Columbia, SC (M.E.S.); and the Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City (R.W.S.).

References
1. Brown AJ, Dusso A, Slatopolsky E. Vita
min D. Am J Physiol 1999;277:F157-F175.
2. Leyssens C, Verlinden L, Verstuyf A.
Antineoplastic effects of 1,25(OH)2D3 and
its analogs in breast, prostate and colorectal cancer. Endocr Relat Cancer 2013;20:
R31-R47.
3. Feldman D, Krishnan AV, Swami S,
Giovannucci E, Feldman BJ. The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer 2014;14:342-57.
4. Harris DM, Go VL. Vitamin D and colon carcinogenesis. J Nutr 2004;134:Suppl:3463S-3471S.
5. Touvier M, Chan DS, Lau R, et al.
Meta-analyses of vitamin D intake, 25hydroxyvitamin D status, vitamin D receptor polymorphisms, and colorectal cancer
risk. Cancer Epidemiol Biomarkers Prev
2011;20:1003-16.
6. Ma Y, Zhang P, Wang F, Yang J, Liu Z,
Qin H. Association between vitamin D
and risk of colorectal cancer: a systematic
review of prospective studies. J Clin Oncol
2011;29:3775-82.
7. Wei MY, Garland CF, Gorham ED,
Mohr SB, Giovannucci E. Vitamin D and
prevention of colorectal adenoma: a metaanalysis. Cancer Epidemiol Biomarkers
Prev 2008;17:2958-69.
8. Lee JE. Circulating levels of vitamin
D, vitamin D receptor polymorphisms,
and colorectal adenoma: a meta-analysis.
Nutr Res Pract 2011;5:464-70.
9. Chung M, Lee J, Terasawa T, Lau J,
Trikalinos TA. Vitamin D with or without
calcium supplementation for prevention
of cancer and fractures: an updated metaanalysis for the U.S. Preventive Services
Task Force. Ann Intern Med 2011;155:82738.
10. Yin L, Grandi N, Raum E, Haug U,
Arndt V, Brenner H. Meta-analysis: serum

1530

vitamin D and colorectal adenoma risk.
Prev Med 2011;53:10-6.
11. Avenell A, MacLennan GS, Jenkinson
DJ, et al. Long-term follow-up for mortality and cancer in a randomized placebocontrolled trial of vitamin D(3) and/or
calcium (RECORD trial). J Clin Endocrinol Metab 2012;97:614-22.
12. Lappe JM, Travers-Gustafson D, Davies
KM, Recker RR, Heaney RP. Vitamin D
and calcium supplementation reduces cancer risk: results of a randomized trial. Am
J Clin Nutr 2007;85:1586-91.
13. Trivedi DP, Doll R, Khaw KT. Effect of
four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and
mortality in men and women living in the
community: randomised double blind
controlled trial. BMJ 2003;326:469.
14. Wactawski-Wende J, Kotchen JM, Anderson GL, et al. Calcium plus vitamin D
supplementation and the risk of colorectal cancer. N Engl J Med 2006;354:684-96.
15. Pence BC. Role of calcium in colon
cancer prevention: experimental and clinical studies. Mutat Res 1993;290:87-95.
16. Huncharek M, Muscat J, Kupelnick B.
Colorectal cancer risk and dietary intake
of calcium, vitamin D, and dairy products:
a meta-analysis of 26,335 cases from 60 observational studies. Nutr Cancer 2009;61:
47-69.
17. Baron JA, Beach M, Mandel JS, et al.
Calcium supplements for the prevention
of colorectal adenomas. N Engl J Med
1999;340:101-7.
18. Bonithon-Kopp C, Kronborg O, Giacosa A, Räth U, Faivre J. Calcium and fibre
supplementation in prevention of colorectal adenoma recurrence: a randomised intervention trial. Lancet 2000;356:1300-6.
19. Chu DZ, Hussey MA, Alberts DS, et al.
Colorectal Chemoprevention Pilot Study

n engl j med 373;16

nejm.org

(SWOG-9041), randomized and placebo
controlled: the importance of multiple luminal lesions. Clin Colorectal Cancer
2011;10:310-16.
20. Beaty MM, Lee EY, Glauert HP. Influence of dietary calcium and vitamin D on
colon epithelial cell proliferation and
1,2-dimethylhydrazine-induced colon carcinogenesis in rats fed high fat diets. J Nutr
1993;123:144-52.
21. Grau MV, Baron JA, Sandler RS, et al.
Vitamin D, calcium supplementation, and
colorectal adenomas: results of a randomized trial. J Natl Cancer Inst 2003;95:176571.
22. Institute of Medicine Standing Committee on the Scientific Evaluation of
Dietary Reference Intakes. Dietary reference intakes for calcium, phosphorus, magnesium, vitamin D and fluoride. Washington, DC:National Academies Press, 1997.
23. Gandini S, Boniol M, Haukka J, et al.
Meta-analysis of observational studies of
serum 25-hydroxyvitamin D levels and
colorectal, breast and prostate cancer and
colorectal adenoma. Int J Cancer 2011;
128:1414-24.
24. Weinstein SJ, Yu K, Horst RL, Ashby J,
Virtamo J, Albanes D. Serum 25-hydroxyvitamin D and risks of colon and rectal cancer in Finnish men. Am J Epidemiol 2011;
173:499-508.
25. Barry EL, Mott LA, Melamed ML, et al.
Calcium supplementation increases blood
creatinine concentration in a randomized
controlled trial. PLoS One 2014;
9(10):
e108094.
26. Bolland MJ, Avenell A, Baron JA, et al.
Effect of calcium supplements on risk of
myocardial infarction and cardiovascular events: meta-analysis. BMJ 2010;341:
c3691.
Copyright © 2015 Massachusetts Medical Society.

October 15, 2015

The New England Journal of Medicine
Downloaded from nejm.org at DARTMOUTH HITCHCOCK MED CTR on October 15, 2015. For personal use only. No other uses without permission.
Copyright © 2015 Massachusetts Medical Society. All rights reserved.

